AstraZeneca is paying $20 million to Ionis to gain commercialization rights in Latin America for a drug waiting for the FDA’s signoff. Ionis said Friday
Alkermes is flying high into the second half of 2023 with its updated yearly guidance, thanks in part to back royalties and interest from an
Ribon Therapeutics, a biotech looking to make next-generation oral PARP inhibitors, has ended preclinical and platform work to focus on two clinical programs. “Cuts across
Biogen and its new CEO are finally wading into 2023’s M&A wave with a $7.3 billion deal for Reata Pharmaceuticals, which just secured FDA approval
Cyrus Mozayeni has been around the biotech business long enough not to be fazed when things don’t go as expected. Soon after he closed his
AstraZeneca’s Alexion subsidiary is snapping up a suite of Pfizer’s preclinical gene therapies in a move to expand its toolkit in rare disease R&D. The
Gene editing and gene therapy maker Homology Medicines is letting go nearly all of its staff, ending clinical development and searching for a buyer or
Lawmakers clashed over the safety of gender-affirming care in minors on Thursday, during a hearing of the House Judiciary Subcommittee on the Constitution and Limited
The PD-1 inhibitor camrelizumab combined with the VEGFR2-targeted inhibitor rivoceranib (also known as apatinib) significantly improved survival compared with sorafenib (Nexavar) alone for the treatment
Despite alpha-gal syndrome (AGS), or tick bite meat allergy, rising over the last several years and affecting many people in the U.S., many healthcare providers